<p>In this episode, we bring you an interview with Professor Elias Arnér from the Karolinska Institute. After a long international career in redox biology, Professor Arnér became CEO of Thioredoxin Systems, the company behind a potential new antibiotic with a novel target and mode of action: EbsArgent. We explore his background, the lessons he has learned, and what makes this new drug candidate so unique. </p><p>In the news section, Elin brings us a recent article on the resistance and potential collateral sensitivity of Ceftazidime-avibactam to treat P. aeruginosa strains. Eva shares the latest publication at our center, with PhD student Adrián González López’s work on the mechanisms behind FusB-mediated resistance in Staphylococcus aureus. </p><p>We hope you enjoy this month’s episode, and see you on the next one! </p><p>Check relevant links in the <a href="https://www.uu.se/en/centre/uppsala-antibiotic-center/communication/the-amr-studio/episode-61" target="_blank" rel="ugc noopener noreferrer">show notes here.</a> Follow our updates on <a href="https://x.com/uac_uu" target="_blank" rel="ugc noopener noreferrer">⁠twitter/X</a> &amp; <a href="https://bsky.app/profile/uac-uu.bsky.social" target="_blank" rel="ugc noopener noreferrer">Bluesky⁠</a> with #theAMRstudio hashtag! Theme music by <a href="http://www.tinyurl.com/henriknissspotify" target="_blank" rel="ugc noopener noreferrer">⁠Henrik Niss⁠</a>.</p>